.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Update on MRD Testing in Acute Lymphoblastic Leukemia

EP. 1: Prognostic Factors in Acute Lymphoblastic Leukemia

February 1st 2020

EP. 2: Considering Induction Regimens for ALL

February 1st 2020

EP. 3: Induction Strategies for Philadelphia-Positive ALL

February 1st 2020

EP. 4: ALL: Cytogenetics and T-Cell Versus B-Cell Induction Strategies

February 1st 2020

EP. 5: Acute Lymphoblastic Leukemia: Optimal Timing of HSCT

February 1st 2020

EP. 6: MRD in ALL: Prognostic Importance and Multidisciplinary Care

February 1st 2020

EP. 7: ALL: When and Who to Test for Minimal Residual Disease

February 1st 2020

EP. 8: Strategies to Assess Minimal Residual Disease

February 1st 2020

EP. 9: Sensitivity of MRD Testing and Impact on Decisionmaking in ALL

February 1st 2020

EP. 10: MRD's Impact on Subsequent Therapy Choice in ALL

February 1st 2020

EP. 11: MRD+ ALL: Evolving Role of BiTE Therapy

February 1st 2020

EP. 12: Optimizing Use of Maintenance Therapy in ALL

February 1st 2020

EP. 13: Future Directions for MRD Testing in ALL

February 1st 2020

EP. 14: MRD Testing in Hematologic Malignancies Other Than ALL

February 1st 2020

EP. 15: Acute Lymphoblastic Leukemia: Future Directions in Therapy

February 1st 2020